secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0000950170-25-105487
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology Q2 net loss $41.4M; jury kills ANI royalties; BOND-003 75.5% CR
---------------------------------------------------------------------------

- Net loss $41.4M ($0.54/sh) vs $18.9M ($0.28/sh) year ago; R&D $31.3M, G&A $17.4M.
- Cash $661.1M; runway into 1H'28; BLA submission for cretostimogene planned in Q4'25.
- Jury unanimously ruled CG owes no future royalties to ANI, eliminating 5% commercial royalty.
- BOND-003 Cohort C: 75.5% CR at any time; 12-mo CR 50.7%, 24-mo CR 42.3% (K-M); median DOR 28 mo.
- CORE-008 Cohort CX (cretostimogene + gemcitabine) initiated in HR BCG-exposed NMIBC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025105487/0000950170-25-105487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025105487/ck0001991792-20250808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer